Hypereosinophilic syndrome

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
R Respiratory (ATC R) 1
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune, humanized) 1 substance
Monoclonal antibody 1 substance
Phase III: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

3 trials
  • AstraZeneca AB Commercial
    BENRALIZUMAB
    2023-508533-14-00 3 countries n=7
    Pending
  • Glaxosmithkline Research & Development Limited Commercial
    IMP not specified
    2023-510110-36-00 2 countries 2022 n=7
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    DEPEMOKIMAB
    2023-510346-25-00 9 countries 2022 n=36
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Glaxosmithkline Research & Development Limited Commercial 2 Phase III 1
AstraZeneca AB Commercial 1 Phase III 0
New trials by year
2022
2
← All indication landscapes